Gland Pharma Ltd - 543245 - Receipt Of EIR From The US FDA For Company''s VSEZ Sterile Oncology Facility, Visakhapatnam
Receipt of Establishment Inspection Report (EIR) from the US FDA for Company''s VSEZ Sterile Oncology Facility at Visakhapatnam, indicating the closure of the inspection Gland Pharma: What has driven the 85 per cent upside in the stock since the lows in May?
US on recovery track, acquisition delivering on expected lines
Big movers on D-Street: What should investors do with Venky's, Gland Pharma and Lux Industries?
Stocks that were in focus included names like Venky's, which gained 0.32%, Gland Pharma, which jumped 4.96%, and Lux Industries, whose shares declined 2.14% on Tuesday. Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor meeting Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement pertaining to Audited Financial Results of Q2FY24
Gland Pharma soars 5% on in-line Q2 results; should buy, hold or sell the stock?
Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies. Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter and half year ended September 30, 2023
Gland Pharma Results Earnings Call for Q2FY24
Conference Call with Gland Pharma Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript. Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Gland Pharma Ltd.
Pharmaceuticals company Gland Pharma announced Q2FY24 & H1FY24 results: 1. Financial Performance: - Gland Pharma's Q2FY24 revenue stood at Rs 13,734 million, representing a YoY growth of 32%. - The company achieved a net profit of Rs 1,941 million during Q2FY24. - Revenue for H1FY24 was Rs 25,821 million, a 36% increase compared to the previous year. 2. Gross Profit Margin and EBITDA: - Gland Pharma reported a gross profit margin of 63% in Q2FY24, higher than the previous year. - The EBITDA margin for the quarter was 23%. - Cenexi, a subsidiary of Gland Pharma, showed a gross profit margin of 77% despite an operational shutdown. 3. Geographic Revenue Breakdown: - The USA accounted for 54% of Q2FY24 revenue, down from 65% in the same quarter last year. - Europe and Rest of the World (ROW) markets saw growth due to the inclusion of Cenexi. - India contributed to 6% of Q2FY24 revenue. 4. R&D; Expenditure: - Gland Pharma spent Rs 351 million on research and development in Q2FY24. - The company filed 1 ANDA and received approval for 5 ANDAs during the quarter. 5. Capex: - Gland Pharma invested a total of Rs 971 million in capital expenditure during Q2FY24. Commenting on the results, Srinivas Sadu, MD & CEO, Gland Pharma, said, “We ended the first half of FY24 with revenue of Rs 25,821 million, a 36% year-over-year increase, and a net profit of Rs 3,882 million. Pricing and market share trends have shown encouraging indicators of normalization in our key products, contributing to our revenue growth. The overall business stability is restoring confidence, and we stay optimistic about future growth with the forthcoming launches, portfolio expansion, and entry into new markets via a partner-led strategy. Considering the annual summer shutdown in France & Belgium, revenues at Cenexi are in line with our estimates; However, the gross contribution margins saw a sequential improvement. Cenexi remains a strategic asset with a distinctive acquisition thesis, and we are committed to instituting effective measures and new investments to optimize operations and deliver long-term value to our shareholders.” Result PDF Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q2FY24 Financial Results